ECHELON-2 Trial Demonstrates “Practice-Changing” Results for Peripheral T-Cell Lymphomas
ECHELON-2 is the first study in patients with PTCL to show an improvement in overall survival over a standard therapy such as CHOP
Lymphoma News
FDA Approves Ibrutinib (IMBRUVICA) in Combination with Obinutuzumab (GAZYVA) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
New York, NY –The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) in combination with obinutuzumab (GAZYVA) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This…
U.S. Food and Drug Administration Approves Brentuximab Vedotin (ADCETRIS) for Frontline Treatment of Peripheral T-Cell Lymphoma (PTCL)
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has expanded the approved use of brentuximab vedotin (ADCETRIS) injection in combination with chemotherapy for adult patients with previously untreated systemic anaplastic large cell lymphoma (ALCL) and…
In Memoriam: Paul Allen
The Lymphoma Research Foundation extends its heartfelt condolences to the family, loved ones and colleagues of Paul Allen. Mr. Allen contributed greatly to science, philanthropy and business and was committed to improving people’s lives and strengthening communities around the world. Our…
U.S. Food and Drug Administration Approves Duvelisib (COPIKTRA) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of duvelisib (COPIKTRA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after…
U.S. Food and Drug Administration Approves Ibrutinib (IMBRUVICA) Plus Rituximab (RITUXAN) for Waldenström Macroglobulinemia (WM)
New York, NY (August 27, 2018) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) plus rituximab (RITUXAN) for the treatment of adult patients with Waldenström macroglobulinemia (WM). This approval represents the…
U.S. Food and Drug Administration Approves Mogamulizumab-kpkc (Poteligeo) for Two Most Common Types of Cutaneous T-Cell Lymphoma
New York, NY (August 8, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of Mogamulizumab-kpkc (Poteligeo) for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after…
U.S. Food and Drug Administration Approves Pembrolizumab (Keytruda) for Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)
New York, NY (June 13, 2018) –The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed…
U.S. Food and Drug Administration Approves Venetoclax (VENCLEXTA) For Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia – With or Without 17p Deletion
New York, NY (June 8, 2018) – The U.S. Food and Drug Administration (FDA) announced today it has approved the use of venetoclax (VENCLEXTA) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with…
U.S. Food and Drug Administration Approves Tisagenlecleucel For Relapsed/ Refractory Large B-cell Lymphoma
New York, NY (May 1, 2018) –The U.S. Food and Drug Administration (FDA) announced it has approved the use of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (KYMRIAH ®) for the treatment of large B-cell lymphoma after two or…